VRCA, US92511W2070

Lake Street keeps Buy rating for Verrica Pharmaceuticals stock

Published on 10/15/2026 at 13:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Verrica presents YCANTH data on October 15, 2026. Verrica Pharmaceuticals stock costs EUR 3.44 on October 15, 2026, with results due November 9, 2026.

Clinical data and valuation

Verrica's September 30, 2026 release reported a 60.1 percent clearance rate by Day 84.
Lake Street analyst Thomas Flaten set a USD 9.00 target on October 1, 2026.
Verrica Pharmaceuticals stock trades at EUR 3.44 at 1:45 p.m. CEST at Lang & Schwarz on October 15, 2026.

VRCA, US92511W2070, Illustration mit AI erstellt.

Verrica Pharmaceuticals (US92511W2070) is trading at EUR 3.44 at Lang & Schwarz on October 15, 2026, while Lake Street has kept its Buy rating and set a USD 9.00 price target. The analyst view was reported on October 1, 2026 by The Globe and Mail.

Clinical evidence adds a concrete metric

Verrica's September 30, 2026 release said YCANTH achieved complete clearance by Day 84 in 60.1 percent of patients, compared with 19.9 percent for vehicle. The company also reported a hazard ratio of 4.06 in a post-hoc pooled analysis of the CAMP-1 and CAMP-2 Phase 3 trials, giving investors a measurable clinical point alongside the analyst target. The figures come from Verrica Pharmaceuticals.

Three events frame the stock

On September 30, 2026, Verrica announced the YCANTH data presentations and disclosed the 60.1 percent versus 19.9 percent Day 84 clearance comparison. On October 1, 2026, Lake Street analyst Thomas Flaten maintained a Buy rating and set a USD 9.00 target. On October 15, 2026, the company was scheduled to present the same VP-102 analysis at the PeDRA Annual Conference, according to the company release.

What dates matter next?

The PeDRA conference runs from October 15 through October 17, 2026, with the VP-102 poster among the listed presentations. The next reporting date shown for Verrica is November 9, 2026, for third-quarter 2026 results, according to TradingView. The company develops and commercializes dermatology medicines, including YCANTH for molluscum contagiosum and VP-315 for skin cancer research.

Valuation remains tied to execution

Lake Street's USD 9.00 target is more than twice the current Nasdaq quote of USD 3.83 from October 14, 2026, but Verrica remains a development-stage pharmaceutical company with clinical and commercial execution risks. Its market capitalization was USD 65.8 million on October 14, 2026, and the 52-week range was USD 3.28 to USD 9.82. The current euro quotation provides the German-market reference for the stock.

Verrica Pharmaceuticals was trading at EUR 3.44 at Lang & Schwarz on October 15, 2026 at 1:45 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Verrica Pharmaceuticals stock.